Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hexamethylene bisacetamide as a treatment for T-cell leukemia (T-ALL).

Literature DB >> 18164760

Hexamethylene bisacetamide as a treatment for T-cell leukemia (T-ALL).

Silvia Buonamici, Iannis Aifantis.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2007 PMID： 18164760 PMCID： PMC2593865 DOI： 10.1016/j.leukres.2007.11.018

Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156

Keyword Cloud
References

× No keyword cloud information.

12 in total

1. Notch-1 inhibits apoptosis in murine erythroleukemia cells and is necessary for differentiation induced by hybrid polar compounds.

Authors: L L Shelly; C Fuchs; L Miele
Journal: J Cell Biochem Date: 1999-05-01 Impact factor: 4.429

2. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors: Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal: Science Date: 2004-10-08 Impact factor: 47.728

3. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.

Authors: C W Young; M P Fanucchi; T Declan Walsh; L Baltzer; S Yaldaei; Y W Stevens; C Gordon; W Tong; R A Rifkind; P A Marks
Journal: Cancer Res Date: 1988-12-15 Impact factor: 12.701

4. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

Authors: Madeleine Duvic; Rakshandra Talpur; Xiao Ni; Chunlei Zhang; Parul Hazarika; Cecilia Kelly; Judy H Chiao; John F Reilly; Justin L Ricker; Victoria M Richon; Stanley R Frankel
Journal: Blood Date: 2006-09-07 Impact factor: 22.113

Review 5. Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds.

Authors: P A Marks; V M Richon; R A Rifkind
Journal: Int J Hematol Date: 1996-01 Impact factor: 2.490

Hexamethylene bisacetamide as a treatment for T-cell leukemia (T-ALL).

1. Notch-1 inhibits apoptosis in murine erythroleukemia cells and is necessary for differentiation induced by hybrid polar compounds.

2. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

3. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.

4. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

Review 5. Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds.

Review 6. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia.

7. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).

Review 8. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process.

9. Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines.

10. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.